EHS
EHS

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma




PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #BMS–US FDA Accepts for Priority Review BMS’s Application for Opdivo as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma

Source link

EHS
Back to top button